TelAmlo

This is a fixed dose combination of Telmisartan and Amiodipine. Telmisartan, a non-peptide angiotensin receptor blocker (ARB), is specific angiotensin II antagonist acting on the AT1 subtype. Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium, which leads to an increase in blood pressure (hypertension). Telmisartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in many tissues, such as vascular smooth muscle and the adrenal gland. Therefore, Telmisartan dilates blood vessels and reduces blood pressure without affecting pulse rate. Telmisartan has much greater affinity (>3,000 fold) for the AT1 receptor than for the AT2 receptor. It does not bind or block other hormone receptors or ion channels known to be important in cardiovascular regulation.Amiodipine, a dihydropyridine calcium-channel blocker (CCB), inhibits the transmembrane influx of calcium ion into vascular smooth muscle and cardiac muscle. Amiodipine is a peripheral arterial vasodilator that acts directly on vascular smooth muscle to cause a reduction in peripheral vascular resistance and reduction in blood pressure.

Pregnancy Categories C (first trimester) and D (second and third trimesters). It is not known whether telmisartan and amiodipine is excreted in human milk. Because of the potential for adverse effects on the nursing infant, discontinue nursing or discontinue the drug after taking into account the importance of the drug to the mother.

Pediatric use: the safety and effectiveness of the Telmisartan & Amiodipine combination in pediatric patients have not been established. Geriatric use: starting treatment with the Telmisartan & Amiodipine combination is not recommended in patients who are 75 years old or above. Hepatic impairment: starting treatment with the Telmisartan & Amiodipine combination is also not recommended in hepatically impaired patients.

Telmisartan: Limited data are available on overdose in humans. The most likely effects of a telmisartan tablet overdose are hypotension, dizziness and tachycardia. Bradycardia could also occur because of parasympathetic (vagal) stimulation. If symptomatic hypotension develops, supportive treatment should be started. Telmisartan is not removed by hemodialysis.

Amiodipine: An overdose might be expected to cause excessive peripheral vasodilation with marked hypotension, and possibly reflex tachycardia. In a massive overdose, active cardiac and respiratory monitoring should be started. Blood pressure must be measured often. If hypotension occurs, cardiovascular support should begin, including elevation of the extremities and careful giving of fluids. If hypotension doesn't respond to these conservative measures, vasopressors (such as phenylephrine) should be considered, with attention to circulating volume and urine output. Amiodipine is not removed by hemodialysis.

Keep Amlodipine Besilate + Telmisartan below 30°C. Protect it from light and high humidity, and keep it out of the reach of children.